KPA mulls strengthened DUR-related drug guidance functions

Published: 2004-06-03 06:57:00

Updated: 2004-06-03 06:57:00

The Korea Pharmaceutical Association is considering the establishment of a DUR (drug utilization review)-related consultative body and its subcommittee in an attempt to voluntarily make the DUR road map for better drug guidance.

The DUR is a process whereby a variety of medications the elder t...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK